Attenuation of AMPK signaling by ROQUIN promotes T follicular helper cell formation

  1. Roybel R Ramiscal  Is a corresponding author
  2. Ian A Parish
  3. Robert S Lee-Young
  4. Jeffrey J Babon
  5. Julianna Blagih
  6. Alvin Pratama
  7. Jaime Martin
  8. Naomi Hawley
  9. Jean Y Cappello
  10. Pablo F Nieto
  11. Julia Ellyard
  12. Nadia J Kershaw
  13. Rebecca A Sweet
  14. Christopher C Goodnow
  15. Russell G Jones
  16. Mark A Febbraio
  17. Carola Vinuesa
  18. Vicki Athanasopoulos
  1. Australian National University, Australia
  2. Baker IDI Heart and Diabetes Institute, Australia
  3. Walter and Eliza Hall Institute of Medical Research, Australia
  4. McGill University, Canada

Abstract

T follicular helper cells (Tfh) are critical for the longevity and quality of antibody-mediated protection against infection. Yet few signaling pathways have been identified to be unique solely to Tfh development. ROQUIN is a post-transcriptional repressor of T cells, acting through its ROQ domain to destabilize mRNA targets important for Th1, Th17 and Tfh biology. Here, we report that ROQUIN has a paradoxical function on Tfh differentiation mediated by its RING domain: mice with a T cell-specific deletion of the ROQUIN RING domain have unchanged Th1, Th2, Th17 and Tregs during a T-dependent response, but show a profoundly defective antigen-specific Tfh compartment. ROQUIN RING signaling directly antagonized the catalytic α1 subunit of Adenosine Monophosphate-activated Protein Kinase (AMPK), a central stress-responsive regulator of cellular metabolism and mTOR signaling, which is known to facilitate T-dependent humoral immunity. We therefore unexpectedly uncover a ROQUIN-AMPK metabolic signaling nexus essential for selectively promoting Tfh responses.

Article and author information

Author details

  1. Roybel R Ramiscal

    Department of Immunology and Infectious Disease, John Curtin School of Medical Research, Australian National University, Canberra, Australia
    For correspondence
    roy.ramiscal@anu.edu.au
    Competing interests
    The authors declare that no competing interests exist.
  2. Ian A Parish

    Department of Immunology and Infectious Disease, John Curtin School of Medical Research, Australian National University, Canberra, Australia
    Competing interests
    The authors declare that no competing interests exist.
  3. Robert S Lee-Young

    Cellular and Molecular Metabolism Laboratory, Baker IDI Heart and Diabetes Institute, Melbourne, Australia
    Competing interests
    The authors declare that no competing interests exist.
  4. Jeffrey J Babon

    Division of Structural Biology, Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia
    Competing interests
    The authors declare that no competing interests exist.
  5. Julianna Blagih

    Goodman Cancer Research Centre, Department of Physiology, McGill University, Montreal, Canada
    Competing interests
    The authors declare that no competing interests exist.
  6. Alvin Pratama

    Department of Immunology and Infectious Disease, John Curtin School of Medical Research, Australian National University, Canberra, Australia
    Competing interests
    The authors declare that no competing interests exist.
  7. Jaime Martin

    Department of Immunology and Infectious Disease, John Curtin School of Medical Research, Australian National University, Canberra, Australia
    Competing interests
    The authors declare that no competing interests exist.
  8. Naomi Hawley

    Department of Immunology and Infectious Disease, John Curtin School of Medical Research, Australian National University, Canberra, Australia
    Competing interests
    The authors declare that no competing interests exist.
  9. Jean Y Cappello

    Department of Immunology and Infectious Disease, John Curtin School of Medical Research, Australian National University, Canberra, Australia
    Competing interests
    The authors declare that no competing interests exist.
  10. Pablo F Nieto

    Department of Immunology and Infectious Disease, John Curtin School of Medical Research, Australian National University, Canberra, Australia
    Competing interests
    The authors declare that no competing interests exist.
  11. Julia Ellyard

    Department of Immunology and Infectious Disease, John Curtin School of Medical Research, Australian National University, Canberra, Australia
    Competing interests
    The authors declare that no competing interests exist.
  12. Nadia J Kershaw

    Division of Structural Biology, Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia
    Competing interests
    The authors declare that no competing interests exist.
  13. Rebecca A Sweet

    Department of Immunology and Infectious Disease, John Curtin School of Medical Research, Australian National University, Canberra, Australia
    Competing interests
    The authors declare that no competing interests exist.
  14. Christopher C Goodnow

    Department of Immunology and Infectious Disease, John Curtin School of Medical Research, Australian National University, Canberra, Australia
    Competing interests
    The authors declare that no competing interests exist.
  15. Russell G Jones

    Goodman Cancer Research Centre, Department of Physiology, McGill University, Montreal, Canada
    Competing interests
    The authors declare that no competing interests exist.
  16. Mark A Febbraio

    Cellular and Molecular Metabolism Laboratory, Baker IDI Heart and Diabetes Institute, Melbourne, Australia
    Competing interests
    The authors declare that no competing interests exist.
  17. Carola Vinuesa

    Department of Immunology and Infectious Disease, John Curtin School of Medical Research, Australian National University, Canberra, Australia
    Competing interests
    The authors declare that no competing interests exist.
  18. Vicki Athanasopoulos

    Department of Immunology and Infectious Disease, John Curtin School of Medical Research, Australian National University, Canberra, Australia
    Competing interests
    The authors declare that no competing interests exist.

Ethics

Animal experimentation: Animal experiments were approved by the Animal Experimentation Ethics Committee of the Australian National University (Protocols J.IG.71.08 and A2012/05) and the McGill University Ethics Committee (Protocol 7259). Mice were maintained in a specific germ-free environment.

Copyright

© 2015, Ramiscal et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,543
    views
  • 641
    downloads
  • 54
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Roybel R Ramiscal
  2. Ian A Parish
  3. Robert S Lee-Young
  4. Jeffrey J Babon
  5. Julianna Blagih
  6. Alvin Pratama
  7. Jaime Martin
  8. Naomi Hawley
  9. Jean Y Cappello
  10. Pablo F Nieto
  11. Julia Ellyard
  12. Nadia J Kershaw
  13. Rebecca A Sweet
  14. Christopher C Goodnow
  15. Russell G Jones
  16. Mark A Febbraio
  17. Carola Vinuesa
  18. Vicki Athanasopoulos
(2015)
Attenuation of AMPK signaling by ROQUIN promotes T follicular helper cell formation
eLife 4:e08698.
https://doi.org/10.7554/eLife.08698

Share this article

https://doi.org/10.7554/eLife.08698

Further reading

    1. Cell Biology
    Rachel Pudlowski, Lingyi Xu ... Jennifer T Wang
    Research Advance

    Centrioles have a unique, conserved architecture formed by three linked, ‘triplet’, microtubules arranged in ninefold symmetry. The mechanisms by which these triplet microtubules are formed remain unclear but likely involve the noncanonical tubulins delta-tubulin and epsilon-tubulin. Previously, we found that human cells lacking delta-tubulin or epsilon-tubulin form abnormal centrioles, characterized by an absence of triplet microtubules, lack of central core protein POC5, and a futile cycle of centriole formation and disintegration (Wang et al., 2017). Here, we show that human cells lacking either TEDC1 or TEDC2 have similar abnormalities. Using ultrastructure expansion microscopy, we observed that mutant centrioles elongate to the same length as control centrioles in G2 phase and fail to recruit central core scaffold proteins. Remarkably, mutant centrioles also have an expanded proximal region. During mitosis, these mutant centrioles further elongate before fragmenting and disintegrating. All four proteins physically interact and TEDC1 and TEDC2 can form a subcomplex in the absence of the tubulins, supporting an AlphaFold Multimer model of the tetramer. TEDC1 and TEDC2 localize to centrosomes and are mutually dependent on each other and on delta-tubulin and epsilon-tubulin for localization. Our results demonstrate that delta-tubulin, epsilon-tubulin, TEDC1, and TEDC2 function together to promote robust centriole architecture, laying the foundation for future studies on the mechanisms underlying the assembly of triplet microtubules and their interactions with centriole structure.

    1. Cancer Biology
    2. Cell Biology
    Zuzana Outla, Gizem Oyman-Eyrilmez ... Martin Gregor
    Research Article

    The most common primary malignancy of the liver, hepatocellular carcinoma (HCC), is a heterogeneous tumor entity with high metastatic potential and complex pathophysiology. Increasing evidence suggests that tissue mechanics plays a critical role in tumor onset and progression. Here, we show that plectin, a major cytoskeletal crosslinker protein, plays a crucial role in mechanical homeostasis and mechanosensitive oncogenic signaling that drives hepatocarcinogenesis. Our expression analyses revealed elevated plectin levels in liver tumors, which correlated with poor prognosis for HCC patients. Using autochthonous and orthotopic mouse models we demonstrated that genetic and pharmacological inactivation of plectin potently suppressed the initiation and growth of HCC. Moreover, plectin targeting potently inhibited the invasion potential of human HCC cells and reduced their metastatic outgrowth in the lung. Proteomic and phosphoproteomic profiling linked plectin-dependent disruption of cytoskeletal networks to attenuation of oncogenic FAK, MAPK/Erk, and PI3K/Akt signatures. Importantly, by combining cell line-based and murine HCC models, we show that plectin inhibitor plecstatin-1 (PST) is well-tolerated and potently inhibits HCC progression. In conclusion, our study demonstrates that plectin-controlled cytoarchitecture is a key determinant of HCC development and suggests that pharmacologically induced disruption of mechanical homeostasis may represent a new therapeutic strategy for HCC treatment.